XDx Selects Ingenuity Systems for Pathways Solution
News Jul 12, 2007
Ingenuity Systems has announced that XDx has licensed Ingenuity’s flagship solution IPA 5.0. Ingenuity Systems was selected by XDx after a comprehensive evaluation of several pathway analysis products.
XDx is a molecular diagnostics company based in Brisbane, California. The company has developed a new method for noninvasively monitoring the immune system by measuring gene expression in a patient’s peripheral blood. The technology can offer the potential to improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.
"We chose IPA because it best meets our objective to identify and understand biomarkers associated with immune-mediated diseases,” commented Dr. Tod Klingler, VP of Informatics at XDx.
“IPA provides us with access to its extensive knowledge base of gene function information assembled from the scientific literature through easy-to-use tools that our researchers can use to rapidly evaluate candidate biomarkers. Specifically, IPA allows us to make sense of our gene expression data in the context of known immune system interactions and pathways.”
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.